Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
- Global & Regional Combination Cancer Immunotherapy Market Insight Till 2028
- Combination Cancer Immunotherapy Market Opportunity: > USD 15 Billion
- Combination Cancer Immunotherapy Market By 15 Different Cancers
- Insight On Clinically & Commercially Approved Cancer Immunotherapy Combinations
- Patent, Price & Dosage Analysis On Approved Combination Drugs
- Global & Regional Sales Insights On Approved Combination Drugs Till 2028
- Insight on 600 Combination Cancer Immunotherapy Drugs In Clinical Trials
- Insight on 45 Combination Cancer Immunotherapy Drugs Commercially Approved In Market
- Clinical Trials & Patent Insight By Company, Country, Indication & Phase
Download Report: https://www.kuickresearch.com/report-combination-cancer-therapy-market
Immunotherapy is novel cancer therapy that naturally stimulates and strengthens the immune system of the patient to fight the disease. The procedure can be utilized as a treatment option for a variety of cancers such as lung cancer, melanoma, breast cancer, and colorectal cancer among others. The advent of immunotherapy have transformed the paradigm of cancer therapy. However, primary and secondary resistance to single agent immunotherapy often results in treatment failure, and only a minority of patients experience long-term benefits. These challenges have pushed the use of immunotherapeutic drugs in combination therapy.
Studies have revealed that pairing novel immunotherapeutic approaches with other types of cancer treatment such as chemotherapy or radiation, helps to enhance the therapeutic benefits among individuals. In addition, combination immunotherapy improves treatment outcomes and results in superior therapeutic effects, especially when a synergistic anticancer activity is achieved. Apart from this, the combination immunotherapy also tackle the highly complex nature of cancer and reduce the toxicity of the regimen as it allows using individual drugs at reduced dosages at maintained therapeutic efficacy.
Owing to their large number of added benefits, several cancer combination immunotherapy has been granted approval by regulatory bodies. For instance in 2022, Europe Commission has granted approval to Keytruda in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for adults with locally advanced or early-stage triple-negative breast cancer (TNBC) at high risk of recurrence. The approval is based on KEYNOTE-522 trial which demonstrated that the combination prolonged event free survival, thus reducing deaths. Apart from this, several others are present in lat stage trials and are demonstrating promising results.
For instance, a recent phase-III clinical trial demonstrates that treatment with AstraZeneca’s Imfinzi (durvalumab) in combination with neoadjuvant chemotherapy before surgery demonstrated a statistically significant and meaningful improvement in pathologic complete response (pCR) compared to neoadjuvant chemotherapy alone for patients with resectable non-small cell lung cancer (NSCLC). Further, epion Pharmaceuticals also announced the results of nonclinical research study demonstrating that its investigational drug, rencofilstat (CRV431) in combination with PD-1 inhibitor has shown synergistic activity in decreasing liver tumor growth and also extended the survival rate of mouse. In December 2021, US FDA has accepted Hepion Pharmaceutical investigational new drug (IND) application for rencofilstat for the management of hepatocellular carcinoma.
Merck, Novartis, Bayer, Amgen, Eli Lilly and Company, Roche, Pfizer, Bristol Myers Squibb, AstraZeneca, and Johnson & Johnson are the major players influencing global cancer immunotherapy market trends. Several other players have also adopted strategic alliance to maintain a strategic edge in the global market. For instance in 2022, Transgene and Bioinvent announced a clinical trial collaboration and supply agreement with Merck to access the safety and tolerability of oncolytic virus BT-001 in combination with Keytruda in a Phase I/IIa clinical trial for the treatment of patients with solid tumors. Another, BioAtla entered into clinical collaboration with Bristol Myers Squibb to evaluate BioAtla two lead CAB-ADC candidates, BA3011 and BA3021, in combination with Bristol Myers Squibb’s anti-PD-1 therapy, Opdivo.
As per our report findings, the global combination cancer immunotherapy market is expected to surpass US$ 15 Billion by 2028. The rise in cancer prevalence as well as the unmet need to lessen the side effects of existing cancer treatments such as chemotherapy and radiation, are projected to propel the combination cancer immunotherapy market forward. Various preclinical and clinical studies are ongoing which are expected to enhance the revenue of the products in coming years. Moreover, the patent expiration of the drugs will also enable the introduction of cost effective biosimilars, which will also have a positive impact on the growth of market.